This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Kansas
Licensed Kansas practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Kansas buyers need their own professional license and NPI; the wholesale distributor registration is the supplier’s obligation, not the purchaser’s.
Kansas has an unusual statutory landscape. It is the only state that created a stem cell center by statute, at the University of Kansas Medical Center, and in 2025 it enacted a right to try act for individualized treatments. Knowing what each one actually covers keeps a practice from citing the wrong law.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Kansas? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | SB 250 (2025) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Kansas
ExaVeyra ships to licensed practices in all 50 states, Kansas included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Kansas professional license in good standing, verifiable through the Kansas State Board of Healing Arts or Kansas State Board of Nursing license verification services.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Kansas resale exemption certificate through the Kansas Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Kansas registers wholesale distributors through the State Board of Pharmacy under K.S.A. 65-1643, which makes it unlawful to distribute drugs or devices at wholesale without first obtaining a registration from the board, and separately requires out-of-state manufacturers shipping into Kansas to register as manufacturers. The regime is broader than most: it reaches devices as well as drugs. The board sets the registration standards, including fees, surety bonds, and designated representative requirements. The registration sits with the distributor, not with the purchasing practice.
K.S.A. 65-1643 · Kansas State Board of Pharmacy
Kansas regenerative-medicine law
Kansas enacted SB 250.
Physicians licensed by the State Board of Healing Arts recommending, and manufacturers operating within an eligible facility providing, individualized investigational treatments to eligible patients: those with a life-threatening or severely debilitating illness who have considered FDA-approved options, received a physician recommendation grounded in analysis of their own genomic sequence or related molecular profile, and given written informed consent. The facility must operate under a Federalwide Assurance for the Protection of Human Subjects. SB 250 is an access statute with eligibility gates, not an authorization of elective regenerative services in a clinic setting. Kansas reached it without ever enacting a generic right to try act: HB 2004 (2015) and HB 2022 (2017) both failed, so before 2025 only the federal Right to Try Act of 2018 applied here.
- Individualized investigational treatments produced for a single patient, based on that patient’s own genetic profile
- Eligible patients with a life-threatening or severely debilitating illness as defined in 21 C.F.R. 312.81, attested by the treating physician
- Eligible facilities operating under a Federalwide Assurance for the Protection of Human Subjects
- Written, informed consent attested by the physician and an unaffiliated witness
- Biospecimen consent and profit-sharing: a facility must obtain consent, and agree profit-sharing terms, before commercializing a product developed from a patient’s biospecimen
“"Individualized investigational treatment" means drugs, biological products or devices that are unique to and produced exclusively for use on an individual patient, based on the patient's own genetic profile. "Individualized investigational treatment" includes, but is not limited to, individualized gene therapy antisense oligonucleotides (ASO) and individualized neoantigen vaccines.”
How this applies to exosomes
Neither Kansas statute in this area reaches exosomes. The right to try for individualized treatments act covers products produced exclusively for one patient from that patient’s own genetic profile, naming antisense oligonucleotides and neoantigen vaccines as its examples; a manufactured exosome product supplied to a clinic is not individualized to one patient’s genome, and unlike Louisiana’s counterpart the Kansas definition carries no perinatal tissue or secreted factor language at all. The Midwest Stem Cell Therapy Center statute, K.S.A. 76-835 and 76-836, directs a university to run a research and treatment center and authorizes nothing outside it. Exosomes are acellular extracellular vesicles, and no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Kansas practice
Because qualifying advanced practice registered nurses hold independent authority in Kansas, there are two workable structures rather than one. An APRN-led practice can evaluate and order within APRN scope under K.S.A. 65-1130. A physician-led practice delegates conventionally, and a medical director is still needed where a procedure falls outside APRN scope or where a payer requires one. Physicians and PAs verify through the Board of Healing Arts, nurses through the Board of Nursing.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Kansas State Board of Healing Arts under the healing arts act, K.S.A. 65-2801 et seq., may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | Kansas advanced practice registered nurses practice independently. Senate Substitute for HB 2279, effective 1 July 2022, amended K.S.A. 65-1130 to remove the responsible physician and written protocol requirements, so an APRN may prescribe, procure, and administer drugs consistent with their role, with DEA registration for controlled substances and malpractice insurance as licensure conditions. |
| PA | Physician assistants are licensed by the Kansas State Board of Healing Arts under the physician assistant licensure act and practice in the scope established with their supervising physician; confirm current agreement requirements with the board. |
| RN | Registered nurses may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
Kansas expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Since July 2022 that provider can be an independently practicing APRN. Confirm current expectations with the Kansas State Board of Healing Arts and the Kansas State Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Kansas recognizes the corporate practice of medicine doctrine through case law under the healing arts act rather than a single codified prohibition, and it allows professional corporations and recognized employment settings alongside management services arrangements. Because the boundaries come from decisions and board positions rather than a bright-line statute, structure ownership with Kansas counsel and the State Board of Healing Arts rather than from a summary.
Cold chain into Kansas
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Kansas order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Overland Park | Johnson | Largest Johnson County market on the Kansas side of the Kansas City metro. |
| Wichita | Sedgwick | Largest city in Kansas, with broad clinical coverage. |
| Kansas City | Wyandotte | Home of the University of Kansas Medical Center and the statutory stem cell center. |
| Topeka | Shawnee | State capital market. |
| Lawrence | Douglas | University market between Topeka and Kansas City. |
| Leawood | Johnson | Johnson County suburb with a concentration of aesthetic practices. |
- Kansas orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every vial arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot, and storage on arrival follows those instructions.
Wholesale exosome supply by city in Kansas
Each city page covers local receiving conditions, delivery disruptions and business license rules for Kansas practices in that area.
Practice types we supply in Kansas
Kansas licensing and verification
Kansas State Board of Healing Arts
Licenses physicians and physician assistants under the healing arts act.
Kansas State Board of Nursing
Licenses RNs and independently practicing APRNs.
Kansas State Board of Pharmacy
Registers wholesale distributors and out-of-state manufacturers under K.S.A. 65-1643.
Kansas Department of Revenue
Sales tax registration and resale exemption certificates.
Kansas sourcing questions
- Does Kansas have a stem cell law?
- Kansas has a stem cell center law, which is a different thing. K.S.A. 76-835 and 76-836, enacted in 2013, direct the University of Kansas Medical Center to establish and run the Midwest Stem Cell Therapy Center for adult, cord blood, and related non-embryonic stem cell research and treatment. The statute governs a university research center and authorizes no clinical service outside it. Exosome products in Kansas are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- What is the Kansas right to try for individualized treatments act?
- SB 250, which became law in 2025 without the governor’s signature, lets a manufacturer operating within a facility that holds a Federalwide Assurance make an individualized investigational treatment available to an eligible patient: someone with a life-threatening or severely debilitating illness, after a physician recommendation based on the patient’s own genetic analysis and written informed consent. It also requires consent and profit-sharing terms before a facility commercializes a product developed from a patient’s biospecimen. It is an access statute with eligibility gates, not an authorization of elective regenerative services.
- Did Kansas ever pass a generic right to try act?
- No. HB 2004 (2015) was stricken from the House calendar and HB 2022 (2017) died in committee, so Kansas reached 2025 without a state right to try statute, and only the federal Right to Try Act of 2018 applied. The 2025 act covers individualized treatments produced for a single patient, which is a narrower subject than the generic acts other states enacted.
- Can a nurse practitioner run a practice in Kansas without a physician?
- Yes, within APRN scope. Senate Substitute for HB 2279, effective 1 July 2022, amended K.S.A. 65-1130 to remove the responsible physician and written protocol requirements, so qualifying APRNs evaluate, order, and prescribe independently, with DEA registration for controlled substances and malpractice insurance as licensure conditions. A medical director is still needed where a procedure falls outside APRN scope or where a payer requires one.
- Does my Kansas clinic need a wholesale distributor registration to buy exosomes?
- No. The wholesale distributor registration under K.S.A. 65-1643 is held by the distributor shipping into Kansas, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Kansas?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- K.S.A. 65-1643, registration of wholesale distributors and out-of-state manufacturers (accessed 16 October 2026)
- K.S.A. 65-1130, advanced practice registered nurses (accessed 16 October 2026)
- K.S.A. 76-835, Midwest Stem Cell Therapy Center, establishment (accessed 16 October 2026)
- K.S.A. 76-836, Midwest Stem Cell Therapy Center, director and reporting (accessed 16 October 2026)
- Kansas SB 250 (2025), right to try for individualized treatments act, enrolled bill (accessed 16 October 2026)
- Kansas Legislature, HB 2022 (2017) bill history, died in committee (accessed 16 October 2026)
- Kansas State Board of Nursing (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this Kansas guide describes.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: ISEV position defining MSC-derived small extracellular vesicles, the product class behind the perinatal MSC-EV source material this page distinguishes from the stem cells Kansas legislated about.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: ISEV position on manufacturing and safety documentation for EV-based products in trials, supporting this page’s framing that clinical exosome use runs through regulated research, not the Kansas access statute.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.